Full-Time

Field Reimbursement Manager

Migraine, Philadelphia Region

Posted on 9/27/2025

Axsome Therapeutics Inc

Axsome Therapeutics Inc

501-1,000 employees

Biopharmaceutical company developing CNS therapies

Compensation Overview

$130k - $165k/yr

+ Bonus

Philadelphia, PA, USA

In Person

Must live in territory geography; up to 50-75% travel including overnight.

Category
Consulting (1)
Required Skills
Sales
Requirements
  • Bachelor’s Degree required; graduate degree preferred
  • Minimum of 8 years of healthcare, field customer, and/or account management experience in the pharmaceutical industry with a minimum of 2 years as an FRM or RAM working specifically with retail medications (preferably with neurology experience)
  • Must live in the territory’s geography
  • Ability to travel up to 50-75% required, which may include overnight travel
  • Pharmacy benefit knowledge required, identifying, and educating to payer criteria for prior authorization
  • Knowledge and understanding of payer segments (e.g., Commercial, Medicare Part D) required
  • CNS/migraine experience strongly preferred
  • Previous experience working in an entrepreneurial environment with launch experience is preferred
  • Experience strategizing within cross-functional teams, utilizing differential resources to achieve business goal
  • Ability to successfully manage multiple tasks concurrently under aggressive timelines in a dynamic environment
  • Demonstrated experience delivering outstanding result
  • Comfortability with uncertainty and lofty expectation
  • Ability to work independently, manage travel schedules, and schedule visits (territory management)
  • Proficient in both virtual and live customer engagement
  • All reimbursement activities must be conducted and managed within all appropriate legal and regulatory guidelines and require continuous monitoring of compliance with such guidelines and laws
Responsibilities
  • Function as a consultant to customers and staff regarding payer policies and processes (i.e., eligibility and benefit verification, prior authorization, and appeals/denials) supporting patient access to Axsome Therapeutics migraine product
  • Educate office staff on the prior authorization process, denial and appeal options, and financial support options for migraine product
  • Proactively engage with assigned accounts supporting internal/external customer access needs and compliantly engage within assigned geography to support access and adherence needs
  • Ability to develop strong relationships with customers by understanding their needs and delivering solutions to overcome obstacles
  • Expert on Axsome Therapeutics patient support programs, payer utilization management, access issue resolution, and financial assistance
  • Collaborate effectively with Managed Markets and Sales to address access challenges and issues.
  • Communicate access concerns and issues with relevant internal stakeholders, including Managed Market
  • Develop and keep updated knowledge of the local and national payer landscape
  • Proficient in both virtual and live customer engagements
  • Communicate territory activity in an accurate and timely manner as directed by management
  • Assist in educating sales colleagues on product access and patient support programs, as needed
  • Complete all training classes
  • Complete administrative duties in an accurate and timely fashion
  • Effectively collaborate across all corporate functions
  • Overnight travel as indicated by the needs of the business
  • All reimbursement activities must be conducted and managed within all appropriate legal and regulatory guidelines and require continuous monitoring of compliance with such guidelines and laws
  • Additional responsibilities as assigned
Desired Qualifications
  • CNS/migraine experience strongly preferred
  • Previous experience working in an entrepreneurial environment with launch experience is preferred
  • Pharmacy benefit knowledge required, identifying, and educating to payer criteria for prior authorization
  • Knowledge and understanding of payer segments (e.g., Commercial, Medicare Part D) required
  • Experience strategizing within cross-functional teams, utilizing differential resources to achieve business goal
  • Ability to successfully manage multiple tasks concurrently under aggressive timelines in a dynamic environment
  • Demonstrated experience delivering outstanding result
  • Comfortability with uncertainty and lofty expectation
  • Ability to work independently, manage travel schedules, and schedule visits (territory management)
  • Proficient in both virtual and live customer engagement
  • All reimbursement activities must be conducted and managed within all appropriate legal and regulatory guidelines and require continuous monitoring of compliance with such guidelines and laws
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders and focuses on research, development, and commercialization of medicines. Its lead product candidate, AXS-05, is an oral NMDA receptor antagonist being developed to treat major depressive disorder (MDD) and treatment-resistant depression (TRD). The company moves its pipeline through clinical trials and regulatory approvals to bring therapies to patients and earns revenue from drug sales, partnerships, and licensing. It differentiates itself by pursuing CNS-focused therapies with NMDA receptor targets and by pursuing designations like FDA Breakthrough Therapy to speed development, with a goal of improving patient outcomes and quality of life.

Company Size

501-1,000

Company Stage

IPO

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Auvelity Q1 2026 revenue hit $153.2M, up 59%, with $8B peak sales outlook post-Alzheimer's approval.
  • Total Q1 2026 revenue reached $191M, up 57%, beating estimates via sales force expansion.
  • Pipeline advances with AXS-12 NDA submission and AXS-20 addition for schizophrenia.

What critics are saying

  • Symbravo loses share to generic triptans and gepants due to high FDC pricing in 6-12 months.
  • AXS-12 NDA fails FDA approval from weak Phase III data, dropping stock 30-50% in 12-18 months.
  • Cash burns $305M reserves from sales force doubling before profitability in 18-24 months.

What makes Axsome Therapeutics Inc unique

  • Auvelity targets NMDA receptors for MDD and Alzheimer's agitation with FDA approvals.
  • Symbravo combines meloxicam-rizatriptan for acute migraine with long-term MOVEMENT trial benefits.
  • Sunosi treats narcolepsy daytime sleepiness with expanding Phase 3 indications.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Yahoo Finance
Apr 8th, 2026
Axsome Therapeutics surges 33% annually since 2015 IPO, eyes $16B peak sales

Axsome Therapeutics, a midcap biotech, has delivered a compound annual growth rate of 33.32% since its 2015 IPO, potentially turning a $50,000 investment into nearly $1 million. However, replicating this performance over the next decade would require the company to reach a market capitalisation of approximately $157 billion. The company's 2025 revenue grew 66% year over year to $638.5 million, driven primarily by Auvelity, a depression treatment. Auvelity may soon receive approval for treating agitation in Alzheimer's disease, expanding its addressable market to over five million US patients. Axsome Therapeutics' pipeline includes several phase 3 assets targeting over 150 million patients, with predicted peak sales exceeding $16 billion. Whilst the company shows promise for long-term growth through the 2040s, matching its historical performance remains unlikely.

Bitget
Mar 18th, 2026
Superstring Capital invests $6.84M in CNS pharma Axsome Therapeutics, stock up 27%

Superstring Capital Management invested $6.84 million in Axsome Therapeutics, purchasing 37,433 shares during Q4 2025, according to a SEC filing dated 17 February 2026. The investment represents nearly 4% of the fund's reported 13F assets. Axsome Therapeutics, a clinical-stage biopharmaceutical company, develops treatments for central nervous system conditions including major depressive disorder, migraines and narcolepsy. The company has commercialised several treatments and recently launched a Phase 3 trial for solriamfetol in major depressive disorder with excessive daytime sleepiness. Axsome shares traded at $158.40 on Wednesday, up 27% over the past year, outpacing the S&P 500's 19% gain. The company reported $638.5 million in annual revenue, a 66% increase from 2024, with a market capitalisation of $8.1 billion.

Yahoo Finance
Mar 18th, 2026
Superstring Capital bets $6.8M on CNS drugmaker Axsome as Phase 3 trial begins and shares climb 27%

Superstring Capital Management has disclosed a new $6.84 million position in Axsome Therapeutics, acquiring 37,433 shares during the fourth quarter of 2025. The stake represents nearly 4% of the fund's assets under management. Axsome Therapeutics, a biopharmaceutical company specialising in central nervous system disorder treatments, has seen its shares rise 27% over the past year to $158.40. The company generated $638.5 million in revenue over the trailing twelve months, representing 66% growth from 2024. The company markets therapies for depression, migraine and sleep disorders whilst advancing a late-stage pipeline. Axsome recently initiated a Phase 3 trial for solriamfetol targeting major depressive disorder with excessive daytime sleepiness, a segment with no approved treatments currently available.

Yahoo Finance
Mar 12th, 2026
Axsome's Auvelity surpasses $500M revenue, eyes approval for Alzheimer's agitation by April

Axsome Therapeutics reported Auvelity surpassed $500 million in revenue during its third year, with total company sales approaching $640 million in 2025. Auvelity posted approximately 68% year-over-year growth. The company's supplemental NDA for AXS-05 (Auvelity) in Alzheimer's disease agitation is under priority review, with a PDUFA date of 30 April 2026. This represents Axsome's key near-term regulatory catalyst, supported by three positive trials. Axsome is doubling its field force from 300 to 600 representatives by Q2, ahead of a potential launch. The company is advancing seven Phase III trials across multiple indications whilst maintaining approximately $323 million in cash to fund operations.

Yahoo Finance
Mar 6th, 2026
Axsome doubles salesforce to 600 reps as AUVELITY hits $155M quarter ahead of April Alzheimer's decision

Axsome Therapeutics reported $155 million in quarterly revenue for AUVELITY, annualising over $600 million just 13 quarters post-launch, though market penetration remains at approximately 0.2% of the antidepressant market. The company plans to double its salesforce from 300 to 600 representatives to drive uptake and support a potential Alzheimer's agitation launch. Over 50% of AUVELITY prescriptions are now monotherapy, with roughly 15% first-line and 35% first-switch therapy. Primary care clinicians account for about 30% of prescribers. Axsome's supplemental NDA for AXS-05 in Alzheimer's disease agitation is under priority review with an FDA decision expected on 30 April. Management reported revenue growth outpacing operating expenses by 3-to-1 in 2025, demonstrating strong operating leverage despite increased direct-to-consumer spending.

INACTIVE